These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27529514)

  • 1. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
    Hidalgo M; Martinez-Garcia M; Le Tourneau C; Massard C; Garralda E; Boni V; Taus A; Albanell J; Sablin MP; Alt M; Bahleda R; Varga A; Boetsch C; Franjkovic I; Heil F; Lahr A; Lechner K; Morel A; Nayak T; Rossomanno S; Smart K; Stubenrauch K; Krieter O
    Clin Cancer Res; 2018 Apr; 24(7):1536-1545. PubMed ID: 29217526
    [No Abstract]   [Full Text] [Related]  

  • 3. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
    Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
    Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
    Mueller T; Freystein J; Lucas H; Schmoll HJ
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.
    Scheuer W; Thomas M; Hanke P; Sam J; Osl F; Weininger D; Baehner M; Seeber S; Kettenberger H; Schanzer J; Brinkmann U; Weidner KM; Regula J; Klein C
    MAbs; 2016; 8(3):562-73. PubMed ID: 26864324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.
    Bessho H; Wong B; Huang D; Tan J; Ong CK; Iwamura M; Hart S; Dangl M; Thomas M; Teh BT
    Cancer Invest; 2015; 33(8):378-86. PubMed ID: 26115098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.
    Wu X; Jeong EK; Emerson L; Hoffman J; Parker DL; Lu ZR
    Mol Pharm; 2010 Feb; 7(1):41-8. PubMed ID: 19958031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor inhibitors in colon cancer.
    Díaz-Rubio E
    Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.
    Hashizume H; Falcón BL; Kuroda T; Baluk P; Coxon A; Yu D; Bready JV; Oliner JD; McDonald DM
    Cancer Res; 2010 Mar; 70(6):2213-23. PubMed ID: 20197469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
    Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
    Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
    Thomas M; Kienast Y; Scheuer W; Bähner M; Kaluza K; Gassner C; Herting F; Brinkmann U; Seeber S; Kavlie A; Welschof M; Ries S; Weidner KM; Regula JT; Klein C
    PLoS One; 2013; 8(2):e54923. PubMed ID: 23405099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.
    Bohndiek SE; Kettunen MI; Hu DE; Brindle KM
    Cancer Res; 2012 Feb; 72(4):854-64. PubMed ID: 22223844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
    Tai JH; Tessier J; Ryan AJ; Hoffman L; Chen X; Lee TY
    Neoplasia; 2010 Sep; 12(9):697-707. PubMed ID: 20824046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI.
    Boult JKR; Box G; Vinci M; Perryman L; Eccles SA; Jones C; Robinson SP
    Neoplasia; 2017 Sep; 19(9):684-694. PubMed ID: 28780387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
    O'Connor JP; Carano RA; Clamp AR; Ross J; Ho CC; Jackson A; Parker GJ; Rose CJ; Peale FV; Friesenhahn M; Mitchell CL; Watson Y; Roberts C; Hope L; Cheung S; Reslan HB; Go MA; Pacheco GJ; Wu X; Cao TC; Ross S; Buonaccorsi GA; Davies K; Hasan J; Thornton P; del Puerto O; Ferrara N; van Bruggen N; Jayson GC
    Clin Cancer Res; 2009 Nov; 15(21):6674-82. PubMed ID: 19861458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
    NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.